The angioedema treatment market is set to thrive at a strong CAGR of 16.6% during the forecast period. The market is likely to cross a revenue of US$ 19 billion by 2032 while it holds a value of US$ 4.12 billion in 2022.
| Attributes | Details |
|---|---|
| Angioedema Treatment Market Size (2022E) | US$ 4.12 Billion |
| Angioedema Treatment Projected Size (2032F) | US$ 19 Billion |
| Value CAGR (2022 to 2032) | 16.6% |
Healthcare systems around the world are adopting the latest medical technology involving angioedema treatment solutions. The increasing geriatric population is also attributed to abnormal lifestyles and unhealthy eating habits. Furthermore, the rising cases of hereditary angioedema, along with the disorders related to it, such as appendicitis, and gastrointestinal issues, are fueling the sales of angioedema treatment solutions.
Majorly treated with medication, the rising cases of allergic angioedema and idiopathic angioedema fuel the sales of angioedema treatment solutions. The government invests in research and development programs. The higher cases of angioedema in developed nations such as the US and the UK are gaining traction in the angioedema treatment market.
Pharmaceuticals and research organizations work to process novel drugs and supportive treatments for angioedema. These medications improve medical facilities and health insurance along with advanced technology. Thus the market for angioedema treatment will boost in the coming years. The higher awareness of the disease and its complications has made people take the treatment seriously, adopting the angioedema treatment solutions.
Advanced technology states that swelling in hereditary angioedema patients is easily controlled with CRISPR treatment. The newly found CRISPR genome editing technology reduces the frequency of attacks in hereditary angioedema patients. Thus, the high-end research programs launched by governments and private entities help the market for angioedema treatment.
The primary treatment of ACEI-AAE is, first and foremost, discontinuation of the inciting drug and management of the airway. The resolution period lies between 24-72 hours. The rising demand for antihistamines, epinephrine, and steroids is to their requirements in different cases of angioedema. The increased involvement of healthcare facilities in dealing with mid-level diseases faster so that the maximum resources can be saved for chronic diseases fuels the market growth for angioedema treatments.
Allergies affect about 30% of the adults and 40% of children and are increasing day by day. It is the fifth leading cause of chronic diseases affecting approximately 50 million people in the United States. Angioedema is one of the common condition caused due to allergies and show sudden swelling under the skin surface.
It is also sad to be the most dangerous form of hives and can affect hands, feet, lips, eye lids and genitals. There are four different types of angioedema as allergic angioedema, idiopathic angioedema, drug-induced angioedema and hereditary angioedema.
The treatment of angioedema may include a normal physical examination, even though with proper medication angioedema cannot be completely cured but regular drugs can help in preventing the attacks in the patients. Allergic angioedema and idiopathic angioedema can be treated using combination drugs and helped relieving swelling. In case of severe cases of angioedema steroid injections may be needed.
In the United States it was reported that in 2010 the total spending on allergies was US$ 17.5 billion from which food allergies cost about US$ 25 million, thus people having severe allergies and changing life-style can be the major factors contributing the growth of the angioedema treatment market.
The increasing rate of angioedema in the United States and other regions has triggered the demand for hospitalization and advancements in the treatment of angioedema. Though angioedema can be treated, it cannot be completely cured and rapidly increasing allergic conditions can give rise to epidemiology, such factors are responsible for hindering the growth of the market. The crucial challenge for the pharmaceuticals is enhance and advance the treatment for angioedema and come up with better drugs.
Globally the number of allergies and allergy conditions as angioedema are rapidly increasing, thus the angioedema treatment market is estimated to have an enormous growth during the forecast period (2016-2026). Pharmaceuticals and research organizations are working to develop novel drug and treatments for angioedema. Improving medical facilities and health insurances along with advance technology the market for angioedema treatment will boost in coming years.
On the basis of region presence, Angioedema Treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Currently, North America dominates the global market for Angioedema Treatment due to high prevalence rate of sinusitis, followed by Europe. According to the epidemiology took place in America in 2010 had increased the hospitalization rate and increasing allergies in adults and children have triggered the growth rate of angioedema. However factors such as climatic conditions inappropriate for angioedema patients and lack of awareness among people about angioedema will hamper the market growth in regions like Asia-pacific and RoW.
Some of the key market players in the manufacturing of the treatment products (drugs) for angioedema treatment includes AstraZeneca plc, F. Hoffmann-La Roche AG, Valeant Pharmaceuticals International, GlaxoSmithKline plc, AstraZeneca Plc, Sanofi S.A and Merck & Co., Inc.
The rising cases of drug-induced angioedema due to the increased application of drugs among all generations adds new elements to the angioedema treatment process. The additions involve the usage of alternative medication and symptoms-based treatment. Furthermore, the increased usage of drugs in the US has pushed healthcare services to focus on minimizing the swelling of the eyes, lips, genitals, hands, and feet. Drug-infused angioedema is diagnosed through blood and allergy tests that determine the type of angioedema.
The global market for Angioedema Treatmentis segmented on basis of treatment and end use:
The market is likely to register a CAGR of 16.6% through 2032.
The market is currently valued at US$ 4.12 Bn in 2022.
The market is likely to grow to a valuation of US$ 19 Bn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Similar Insights
Angioedema Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
